| Methods |
STUDY DESIGN: Parallel group. 6 week treatment period. Single centre ‐ UK.
RANDOMISATION: Yes, method not stated.
BLINDING: Double blind using identical inhalers.
WITHDRAWALS/DROP OUTS: All subjects completed study.
COMPLIANCE: No details.
CONFOUNDERS: None apparent.
QUALITY: Jadad 4. Cochrane B |
| Participants |
N = 20 Adults M = 13,F = 7 Mean age 39 yrs
BASELINE SEVERITY: Symptommatic asthma
INCLUSION : Taking ICS regularly
EXCLUSION:Oral beta agonist/theophylline, ipratropium |
| Interventions |
LONG ACTING BETA AGONIST: Salmterol 50 mcg BD
SHORT ACTING BETA AGONIST: Salbutamol 400 mcg BD
DEVICE: Diskhaler
TREATMENT PERIOD: 6 weeks
RESCUE: Short acting beta2 agonist‐ salbutamol 400 mcg inhalation PRN
CO‐INTERVENTIONS:
All on, ICS‐ mean dose 575 & 610 mcg. |
| Outcomes |
OUTCOMES: FEV1, FVC, PEF, PD20 Methacholine. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
Information not available (Cochrane Grade B) |
